



Medicines & Healthcare products
Regulatory Agency

MHRA Central Freedom of
Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

[MHRA Website](#)

Our Ref: **FOI2025/00492**

21 May 2025

Dear [REDACTED]

Thank you for your Freedom of Information (Fol) request received on 13 May. You wrote:

I write to you to submit a Freedom of Information Request. Please can you furnish me with the following information:

How many Yellow Card Reports you have received which have been categorised using the MedDRA code 10086208 (Post-SSRI sexual dysfunction)?

Can you please break the data down by a) year and b) medication.

MHRA Response

We confirm that we hold the information you have requested and provide it in the format you requested below.

The MHRA has received 70 UK spontaneous suspected adverse drug reaction (ADR) reports coded using the MedDRA term 'post-SSRI sexual dysfunction' up to the 21st May 2025. Please see further details in Table 1 below, which separates these reports out by substance and year, as requested. Please note the total number of reports in Table 1 will not necessarily equal the total number of reports, as one report may include more than one suspect drugs. Post-SSRI sexual dysfunction was added to the Medical Dictionary for Regulatory Activities (MedDRA) in 2021 and therefore only ADR reports received following this date will have had this term available as to code against.

When considering the spontaneous data provided, it is important to be aware of the following points:

- A reported reaction does not necessarily mean it has been caused by the vaccine, medicine, or device only that the reporter had a suspicion it may have. The fact that symptoms occur after use of a vaccine, medicine, or device, and are reported via the Yellow Card scheme, does not in itself mean that they are proven to have been caused by it. Underlying or concurrent illnesses may be responsible and such events can also be coincidental.

- It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction or compare the safety profile of different vaccines, medicines, or devices. ADR and Device incident reporting rates are influenced by the seriousness of adverse reactions, their ease of recognition, the extent of use of a particular medicine or device, and may be stimulated by promotion and publicity. Reporting tends to be highest for newly introduced medicines during the first one to two years on the market and then falls over time.

Table 1: Number of Yellow Card (YC) Reports received since the start of the YC scheme to the 21st May 2025 which report Post-SSRI sexual dysfunction

Year	Substance	Number of Reports
2021	SERTRALINE	1
2022	AMITRIPTYLINE	1
	CITALOPRAM	1
	DULOXETINE	1
	ESCITALOPRAM	1
	FLUOXETINE	2
	LITHIUM	1
	NORTRIPTYLINE	1
	OLANZAPINE	1
	SERTRALINE	2
	VORTIOXETINE	1
2023	CITALOPRAM	4
	DULOXETINE	1
	ESCITALOPRAM	2
	FLUOXETINE	1
	MIRTAZAPINE	1
	SERTRALINE	4
	VENLAFAXINE	1
	VORTIOXETINE	2
2024	CITALOPRAM	3
	ESCITALOPRAM	2
	FLUOXETINE	3
	SERTRALINE	6
	VENLAFAXINE	2
2025	AMITRIPTYLINE	1
	CITALOPRAM	8
	DULOXETINE	2
	ESCITALOPRAM	6
	FLUOXETINE	4
	MIRTAZAPINE	1
	NORTRIPTYLINE	1
	PAROXETINE	2
	PROMETHAZINE	1
	SERTRALINE	6
	VENLAFAXINE	1
	VORTIOXETINE	1

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

Re-use of our information

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>